The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5 0 -DCC 3 0 -MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis.
The genes MBD1 and MBD2 encode methyl-CpG binding proteins that suppress transcription from methylated promoters. In contrast, CGBP encodes a protein that binds promoters containing unmethylated CpG and stimulates transcription. All three are located on human chromosome 18q21, a region of frequent loss of heterozygosity in several cancers. These genes therefore represent candidate tumour suppressor genes, whose loss of function could affect the normal regulation of gene expression, whether by lack of complete suppression of genes normally silenced (via loss of MBD1 and MBD2) or by some loss of activation of genes normally expressed (via loss of CGBP), either way contributing to the tumorigenic phenotype. We have confirmed by fluorescent in situ hybridization that MBD1 and MBD2 bracket the DCC locus giving a gene order of MBD1/CGBP-DCC 5 0 -DCC 3 0 -MBD2. Mutation analyses by single-stranded conformation polymorphism in colon and lung cancer cell lines and primary tumours revealed a small number of mutations, suggesting only a limited role of these genes in human tumorigenesis. Oncogene (2003 Oncogene ( ) 22, 3506-3510. doi:10.1038 Keywords: 18q21 gene mutations; colon cancer; lung cancer
The genes MBD1, MBD2 and CGBP are closely linked on chromosome 18q21. This is a region of the genome known to suffer loss of heterozygosity (LOH) in a significant proportion of cancers, including about 75% colorectal carcinomas (CRC) (Vogelstein et al., 1988 (Vogelstein et al., , 1989 Thiagalingam et al., 1996) for which there are also reports of prognostic significance of 18q21 LOH (Jen et al., 1994; Lanza et al., 1998; Martinez-Lopez et al., 1998) , and 32% small cell (SCLC) and 56-65% nonsmall cell lung carcinomas (NSCLC) (Shiseki et al., 1994; Takai et al., 1998; Virmani et al., 1998) . Three candidate tumour suppressor genes had been cloned previously from this region, DCC (Fearon et al., 1990) , DPC4/SMAD4 and JV18-1/SMAD2 (Riggins et al., 1996) ; however, mutation frequencies of these genes in colorectal and lung carcinomas reported by many groups are lower than the observed LOH and their roles in colorectal tumorigenesis remain controversial (Fazeli et al., 1997; Fabre et al., 1999) . MBD1 and MBD2 were found to lie on human chromosome 18q21 by PCR and fluorescent in situ hybridization (FISH) when originally cloned (Hendrich et al., 1999a) . CGBP was colocalized following the discovery of its 3 0 exon sequences within a PAC containing the promoter region and the CpG island of MBD1 (Cross et al., 1999) .
Methylation of CpG dinucleotides is an important epigenetic mechanism used by vertebrate cells to repress transcription of many tissue-specific genes (Bird, 2002) . MBD1 and MBD2 are members of the MBD family that act as intermediaries in this process, binding to methylCpG and actively recruiting other protein complexes that alter chromatin conformation (via chromatin remodelling and histone deacetylation) to interfere with the transcription process (Jones et al., 1998; Nan et al., 1998; Ng et al., 1999) . One group has also shown that MBD2 is capable of actively demethylating DNA (Bhattacharya et al., 1999) , and its activity as transcriptional repressor or demethylase may depend on the context of the promoter with which it interacts (Detich et al., 2002) . The demethylase activity of MBD2 remains controversial (Ng et al., 1999; Wade et al., 1999; Boeke et al., 2000) , but if true would activate gene transcription by removing the repressive methyl-C signals.
Localized concentrations of CpG dinucleotides, termed CpG islands, are mainly kept unmethylated and are commonly associated with promoters of housekeeping and constitutively expressed genes. How CpG islands are kept unmethylated is not certain, but one mechanism may involve binding of a protein to unmethylated CpG that prevents DNA methylation and its biological consequences. CGBP (CpG-binding protein) may act in this way. CGBP has homology to MBD1 by having one CXXC domain, a domain that is highly conserved among several proteins including also DNA methyltransferase 1 (DNMT1) (Bestor and Verdine, 1994) , human trithorax (HRX) (also known as MLL and ALL-1) (Gu et al., 1992; Tkachuk et al., 1992; Ma et al., 1993; Zeleznik-Le et al., 1994; Prasad et al., 1995) and MLL-2 (FitzGerald and Diaz, 1999) . CGBP has been shown to bind to DNA elements containing unmethylated CpG, and it has further been shown to have transcription activating properties from such unmethylated promoters (Voo et al., 2000) .
Whether involved in repression or activation of transcription, these genes together have a role in maintenance of the gene expression profile in cells and might therefore be considered to be candidate tumour suppressor genes: loss of normal function of MBD1, MBD2 and/or CGBP could lead to abnormal reexpression or silencing of a host of other genes, allowing tumorigenic progression via epigenetic instability. It has been shown that the level of expression of MBD2 (and the MBD prototype MeCP2) is decreased in a variety of primary human tumours including those of the colon (Kanai et al., 1999; Mu¨ller-Tidow et al., 2001) , consistent with an association of MBD2 abnormality with tumorigenicity. Although there is no evidence for increased tumorigenesis in mouse models totally lacking the Mbd2 gene Hendrich et al., 2001) , it was important to conduct a formal study looking for mutations in the human MBD2 gene and its MBD1 and CGBP neighbours.
We first used FISH to ascertain the order of MBD1 and MBD2 genes with respect to DCC. Owing to the proximity of these three genes the signals were not separable on metaphase chromosomes, so we chose to examine interphase nuclei. We used probes from the first and the 26th exons of DCC, which lie approximately 1.3 Mb apart (Cho et al., 1994) , to orient the group with respect to centromere and telomere. PAC probes (Human Genome Mapping Project Resource Centre gridded PAC library screened by PCR) for MBD1, MBD2 and both ends of DCC were labelled with either biotin or digoxygenin for detection with Texas red and FITCconjugated antibodies, respectively. Probes were hybridized in groups of three in all four possible combinations. For each set of three probes, one was labelled and detected simultaneously with both systems to give an overlapping red/green signal. In all, 57 informative interphase nuclei were scored, which included examples from each of the four groups of probes. Examples of informative nuclei are shown in Figure 1 . The MBD2, DCC1 and DCC26 probes gave fairly evenly spaced signals with a consistent probe order of DCC1-DCC26-MBD2. Since the distance between DCC1 and DCC26 is known to be about 1.3 Mb, and since the MBD2 probe appears to be at least as close to the DCC26 probe as is the DCC1 probe, we inferred that the MBD2 gene lies within about 1 Mb of the 3 0 end of DCC. Although the MBD1 signal was clearly more distant to the other three, a probe order of MBD1-DCC1-DCC26-MBD2 was seen in approximately two-thirds of informative nuclei. This places MBD1 probably near to and on the centromeric side of SMAD4, which is itself about 0.7 Mb centromeric to DCC1 . CGBP location was earlier discovered by analysis of a PAC containing the CpG island of MBD1 that showed 3 0 exon sequences of CGBP (Cross et al., 1999) . The integrity of this genomic proximity of CGBP to MBD1 in vivo was confirmed by performing PCR between the gene sequences from total genomic DNA (data not shown). However, CGBP and MBD1 orientation relative to the centromere could not be determined by our analyses. Figure 1 shows our inferred order of genes in the region. This arrangement is in total agreement with mapping data for the genes as presented on the NCBI Genome website for chromosome 18. The human genome project sequence clarifies the orientation of MBD1-CGBP, hence the relative placement of these two genes in our figure.
For the mutation screen by single-stranded conformation polymorphism (SSCP), DNAs were extracted by standard methods from pellets of cell lines, from frozen archival primary tumours and from normal blood samples. Cell lines were obtained from ECACC (the European Collection of Cell Cultures/ATCC) or Drs Minna and Gazdar (University of Texas Southwestern Medical Centre). Seven colon cancer, 47 SCLC, 33 Mutations of MBD1, MBD2 and CGBP genes S Bader et al NSCLC, one carcinoid and one mesothelioma cell lines were used (see Table 1 the full list is available upon request). Primary tumour samples were part of an unselected, anonymized collection from patients at the Royal Infirmary Edinburgh. Normal blood samples from independent healthy donors were obtained from the Scottish National Blood Transfusion Service. Primers were designed for SSCP that spanned each translated exon (overlapping where necessary) and included splice acceptor and donor sites. The total numbers of primer pairs were 17 for MBD1, five for MBD2 and 16 for CGBP (list of sequences available upon request). Standard SSCP PCR and gels, and cycle sequencing were performed as described before (Bader et al., 1999) . We found a large number of differences in our samples with respect to the published sequences for the three genes. Most were either silent, or confirmed as polymorphisms by being seen frequently in other tumour samples and when checked in 100 normal blood samples. Others were predicted to be rare singlenucleotide polymorphisms (SNP) by being seen in normal tissue from the same patient at least but absent from the other individuals studied, for example, in MBD1 of colon primary I9A (Table 2) . It is theoretically possible that the heterozygous sequence differences seen in the cell lines for which no normal tissue DNA was available are also rare SNPs. Allowing for this caveat, however, some mis-sense and nonsense mutations were found in the samples screened (Table 2) . Of interest for MBD1, two mutations were found in cell lines, both of which affected the third CXXC domain. The cell line H1092 mutation is especially interesting as it creates a premature stop codon just proximal to the CXXXXXC motif within the third CXXC domain. This mutation only affects some of the five isoforms of the protein since exon 11 is not included in all splice forms of the gene (Fujita et al., 1999 ), but we know that the relevant transcripts are indeed expressed (cDNA PCR followed by sequencing; data not shown). It is not known exactly what role each isoform plays, but it has been shown that the isoforms containing all three CXXC domains repress gene expression from both unmethylated and methylated promoters, while those that contain just the first two CXXC domains only repress transcription when promoters are methylated (Fujita et al., 1999 (Fujita et al., , 2000 . The mutation in H1092 is predicted to produce truncations in isoforms v1, v2 (Fujita et al., 1999) and exon 7 (Cross et al., 1997) that would have an incomplete third CXXC domain but would also lack the C-terminal transcription repression domain (TRD) and so would not mimic the normal v3 and v4 isoforms. We are currently determining whether the truncated protein isoforms are stable in cells, since, if stable, they may have dominant-negative effects in addition to the partial decline of normal MBD1 levels. Similar truncated proteins made experimentally of the related MeCP2 protein, comprising the prototypical MBD (Nan et al., 1993) , have been shown to be capable of binding to methylated DNA in vitro, as was a similar form of MBD4 (Hendrich et al., 1999b) . Exon 10, T to C T442 Silent polymorphism Misc.
Intron 12, C to A +14 nt Polymorphism a Amino-acid numbering refers to the full-length MBD2a form. het, heterozygous; Constitut, constitutive; misc: miscellaneous; ND, not determined.
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The mis-sense mutation in cell line HCT15 was at a residue with no known significance, but if it significantly altered the structure of the third CXXC domain, this could lead to an important loss of MBD1's ability to repress transcription from unmethylated promoters. The mutation is expressed (cDNA PCR followed by SSCP and/or sequencing; data not shown).
Most of the mutations in MBD2 were located within the overlap of the MBD and Sin3A-interacting (Boeke et al., 2000) regions and one, found in cell line LOVO, was a frameshift mutation that was expressed as seen by cDNA PCR þ sequencing (data not shown), and when translated would produce a truncated protein leaving only the MBD. If stable in living cells, the truncated protein would be predicted to bind to methyl-CpG and exert a dominant-negative effect similar to that predicted for the MBD1 mutation mentioned above. Exon 1, which encodes the N-terminal part of the MBD, was not screened at the time because the region is extremely C/G rich (B75%) and thus awkward to PCR amplify, especially in small segments for SSCP. Although we were later able to PCR amplify the entire 650 bp covering the open reading frame using a high-fidelity polymerase with C/G-rich enhancing additive, this fragment has not yet been found to be amenable to available assays for mutation detection. There is thus scope for further important mutations to be found in this gene since DNA encoding the N-terminal half of the MBD is included in this missing section.
We found few sequence changes in CGBP. The most interesting of these was that found in a primary colon tumour where the conserved exon À1 nt G of the splice acceptor site was altered to an A, predicted to disrupt normal splicing such that exon 5 is simply omitted joining exon 4 to 6. Alternatively, a cryptic splice acceptor site within exon 5 may be used, or some other splicing occurs involving exon skipping around exon 5. The new transcript formed by splicing exons 4 and 6 together would remain in frame, but the protein would lose the CXXC domain with potential changes in protein function. In the more complicated cases depending on how the transcript is spliced, the reading frame may alter, creating a new protein sequence and probably causing a premature truncation and so loss of normal protein function. Attempts continue to PCR amplify between various combinations of primers from cDNA made from RNA extracted from archival frozen tissue of this tumour to look for an aberrant smaller transcript size.
The fact that most of the mutations we found were present only in one allele could have alternative implications: either the mutations are simply random events consequent to the genomic instability occurring in tumour cells and with no selective advantage, or haploinsufficiency of this group of genes is enough to have significance in tumorigenesis. Most of the mutations we found were in MSI cases (colon cancer cell lines HCT15, LOVO, LS180 and primary tumour I17), which have an increased level of mutations but no chromosomal abnormality, while few mutations were found in the MSS colon or lung cancers, even though these tend to lose chromosome 18q21 as seen cytogenetically or by LOH studies. If haploinsufficiency is important here, either mechanism of loss of normal MBD1/MBD2/ CGBP may be effective to reduce the amount of normal protein present. Consistent with this hypothesis, mRNA levels of MBD2 were reduced by 50-66% in colorectal cancers in one study (Kanai et al., 1999) , 20-80% lower in a variety of solid tumours (colon, lung, ovary) (Mu¨ller-Tidow et al., 2001) , significantly reduced in SCLC and NSCLC when normalized to PCNA (Sato et al., 2002) and 25% reduced in hepatocellular carcinomas (Saito et al., 2001) . However, none of these studies looked at the methylation status of the gene. As a common mechanism for abnormal silencing of genes in tumours, demonstration of aberrant methylation would strengthen the significance of partial loss of expression of MBD2 in tumorigenesis. Biallelic loss of these transcription regulatory genes may be rare because it could be lethal. Homozygous loss of CGBP is embryonic lethal (Carlone and Skalnik, 2001) . However, there is a lack of morbid phenotype in mouse knockout models where Mbd2 is lacking Hendrich et al., 2001) , although this may be because of species differences.
In summary, we looked for mutations in the genes MBD1, MBD2 and CGBP involved in the regulation of gene expression that are located on chromosome 18q21 in a region of LOH in tumours. The genes lie intermixed with other candidate tumour suppressor genes DCC, SMAD4, and like them we have found that there is a low frequency of mutation. We conclude that the abnormalities may be merely passenger mutations with no relevance to tumorigenicity, or they reflect further examples of gene abnormalities in that chromosomal region that are important for only a subset of colorectal and lung cancer cases. Analysis of the methylation status of at least MBD2 remains to be carried out to implicate that mechanism as the alternative route by which the gene could play a major role in tumorigenesis.
